Merck Inc. acquires CN 201, a novel CD3xCD19-targeting T-cell-engager bispecific antibody from Curon Biopharmaceutical
Merck Inc,, (known as MSD outside of the United States and Canada), and Curon Biopharmaceutical (Curon), a privately held biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire CN 201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases
Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN2 01 for an upfront payment of $700 million in cash. Curon is also eligible to receive up to $600 million in milestone payments associated with the development and regulatory approval of CN 201.
CN 201 is a novel CD3xCD19-targeting T-cell-engager bispecific antibody, designed to target B cells for elimination by T cells. CN2 01 is currently being evaluated in Phase 1 and Phase 1b/II clinical trials for the treatment of relapsed or refractory non-Hodgkin’s lymphoma and relapsed or refractory acute lymphocytic leukemia, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.